

8. Irodalomjegyzék:

Akerman S, Williamson DJ, Kaube H, Goadsby PJ: Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. *Br J Pharmacol*;137(1):62-8. (2002)

Alsasua del Valle A.: Implication of cannabinoids in neurological diseases. *Cell Mol Neurobiol.*;26(4-6):579-91 (2006)

Annamária Fejes-Szabó, Zsuzsanna Bohár, Enikő Vámos, Gábor Nagy-Grócz, Lilla Tar, Gábor Veres, Dénes Zádori, Márton Szentirmai, János Tajti, István Szatmári, Ferenc Fülöp, József Toldi, Árpád Párdutz, László Vécsei: Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex *J Neural Transm* DOI 10.1007/s00702-013-1146-2 (2013)

Battista N, Di Tommaso M, Bari M and Maccarrone M: The endocannabinoid system: an overview. *Front. Behav. Neurosci.* 6:9. doi: 10.3389/fnbeh..00009 (2012)

Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V: N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. *Biochem J* 351:817-824. (2000)

Blau JN and Dexter SI: The site of pain origin during migraine attacks. *Cephalalgia* 1:143-147 (1981)

Blau JN: Harold G Wolff: The Man and His Migraine *Cephalalgia* vol. 24 no. 3 215-222 (2004)

Brown JH, Kissel JW, Lish PM: Studies on the acute inflammatory response. I. Involment of the central nervous system in certain models of inflammation. *J Pharmacol Exp Ther*;160(1): 231-42.(1968)

Burstein R, Cutrer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. *Brain* 123:1703-1709, (2000)

Burstein R, Collins B, Jakubowski M: Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. *Ann Neurol.* 55:19-26. (2004)

Buzzi MG, Moskowitz MA: The trigemino-vascular system and migraine. *Pathol Biol*; (Paris) 40:313-317. (1992)

Cabral GA, Griffin-Thomas L: Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. *Expert Rev Mol Med* 11:e3. (2009)

Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 389:816-824. (1997)

Chacur M, Matos RJ, Alves AS, Rodrigues AC, Gutierrez V, Cury Y, Britto LR: Participation of neuronal nitric oxide synthase in experimental neuropathic pain induced by sciatic nerve transection. *Braz J Med Biol Res* 43(4):367–376. doi:10.1590/ S0100-879X2010007500019 (2010)

Christian Waeber, Michael A. Moskowitz: Therapeutic implications of central and peripheral neurologic mechanisms in migraine. *Neurology* 61 (Suppl. 4), S. S9 – S20 (2003)

De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, Casari G: Haploinsufficiency of ATP1A2 encoding the Na⁺/K⁺ pump alpha2 subunit associated with familial hemiplegic migraine type 2. *Nat Genet.*;33(2):192-6. (2003)

De Petrocellis L, Harrison S, Bisogno T. et al.: The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. *J Neurochem*; 77: 1660–1663.(2001)

Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258:1946-1949. (1992)

Ellis EF, Moore SF és Willoughby: KA Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. *Am J Physiol*; 269(6 Pt 2): H1859-1864 (1995)

Earleywine, Mitch: Marihuána – a tudomány álláspontja. Edge 2000, Budapest, 197-226. (2004)

Fang L, Wu J, Lin Q, WillisWD: Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. *J Neurosci* 22(10):4196–4204 (pii: 2002634322/10/4196) (2002)

Friberg L, Olesen J, Iversen HK, Sperling B: Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. *Lancet* 338:13-17, (1991)

Freund TF, Katona I, Piomelli D: Role of endogenous cannabinoids in synaptic signaling. *Physiol. Rev.* 83, 1017-1066 (2003)

Folwer CJ: Anandamide uptake explained? *Trends Pharmacol Sci*; 33(4): 181-185 (2012)

Gaetani S, DiPasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V: The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. *Int Rev Neurobiol* 85:57-72. (2009)

Geppetti P and Holzer P: *Neurogenic Inflammation*, CRC Press, Boca Raton, FL (1996)

Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA: Mechanisms of migraine aura revealed by functional MRI in human visual cortex. *Proc Natl Acad Sci (U. S. A.)* 98 (8):4687-92. (2001)

Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, Fernandez-Ruiz JJ, Hansen HS: Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. *J Neurochem* 78:1415-1427. (2001)

Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R: 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. *Proc Natl Acad Sci U S A* 98:3662-3665. (2001)

Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J. Neurosci.* 11, 563–583. (1991)

Hohmann AG, Martin WJ, Tsou K, Walker JM: Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212–2. *Life Sci* 56:2111–2118. (1995)

Holzer P: Capsaicin: cellular targets, mechanisms of action and selectivity for thin sensory neurons. *Pharmacol Rev* 43:143–201. (1991)

Iversen HK, Olesen J, Tfelt-Hansen P: Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. *Pain* 38:17-24,(1989)

Kelm M: Nitric oxide metabolism and breakdown. *Biochimica et Biophysica Acta* 1411:273-289, (1999)

Keidel M: A migrén Okok, fajták, terápiák, München, Corvina Tudástár (2007)

Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J: Nitric oxide synthase inhibition in migraine. *Lancet*; 349(9049):401-2. (1997)

Laviolette SR, Grace AA: The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. *Cell Mol Life Sci*; 63(14):1597-613.(2006)

Lichtman AH, Martin BR: Spinal and supraspinal components of cannabinoid-induced antinociception. *J. Pharmacol. Exp. Ther.* 258, 517–523. (1991)

Lovinger DM: Endocannabinoid liberation from neurons in transsynaptic signaling. *J Mol Neurosci* 33:87-93. (2007)

Mangieri RA, Piomelli D: Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. *Pharmacol Res* 56:360-366. (2007)

Matthias Keidel: A migrén Okok, fajták, terápiák, München, Corvina Tudástár,(2007)

Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50:83-90. (1995)

Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, Mo FM, Offertaler L, Pacher P, Kunos G, Mechoulam R: N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. *Proc Natl Acad Sci U S A* 103:2428-2433 (2006)

Moldrich G, Wenger T: Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. *Peptides*; 21(11):1735-42. (2000)

Moskowitz MA: Neurogenic inflammation in the pathophysiology and treatment of migraine. *Neurology* 43:16-20. (1993)

Moskowitz MA: Defining a pathway to discovery from bench to bedside: the trigeminovascular system and sensitization. *Headache*; 48 (5): 688-90. (2008)

- Murad F:** Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. *Adv Pharmacol*;26:19-33. (1994)
- Ohno-Shosaku T,** Maejima T, Kano M: Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. *Neuron*, vol. 29, 729-738 (2001)
- Okamoto Y,** Morishita J, Tsuboi K, Tonai T és Ueda N: Molecular characterization of phospholipase D generating anandamide and its congeners. *J Biol Chem*; 279(7): 5298-5305.(2004)
- Olesen J,** Thomsen LL, Lassen LH, Olesen IJ: Nitric oxide inhibition in migraine. *Lancet* 349:401-402, (1995)
- Olesen J,** Iversen HK, Thomsen LL: Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. *Neuroreport*, 4, 1027-30. (1993)
- Ophoff RA,** Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNL1A4. *Cell*. 1;87(3):543-52. (1996)
- O'Sullivan SE,** Kendall DA és Randall MD: Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. *Br J Pharmacol*; 142(3):435-442 (2004)
- Otsuka M,** Yoshioka K: Neurotransmitter functions of mammalian tachykinins. *Physiol Rev* 73:229 –308. (1993)
- Pacher P,** Batkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev* 58:389–462. [PubMed: 16968947] (2006)
- Párdutz A,** Krizbai I, Multon S, Vécsei L, Schoenen J: Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. *Neuroreport*; 11 (14):3071-5. (2000)
- Párdutz A,** Multon S, Malgrange B, Parducz A, Vecsei L, Schoenen J: Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen. *European Journal of Neuroscience* 15:1803-1809, (2002)
- Piomelli D:** The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci* 4:873-884. (2003)

Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. *J Pharmacol Exp Ther* 301:1020-1024. (2002)

Pratt PF, Hillard CJ, Edgmond WS és Campbell WB: N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. *Am J Physiol*; 274(1 Pt 2): H375-381 (1998)

Premkumar LS, Ahern GP: Induction of vanilloid receptor channel activity by protein kinase C. *Nature*; 408: 985–990. (2000)

Randall MD és Kendall Da: Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. *Eur J Pharmacol*, 335(2-3):205-209 (1997)

Raskin NH, Hosobuchi Y, Lamb S: Headache may arise from perturbation of brain. *Headache*;27(8):416-20. (1987)

Pertwee RG, Ross RA: Cannabinoid receptors and their ligands Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK (2002)

Richardson JD, Aanonsen L, Hargreaves KM: Antihyperalgesic effects of spinal cannabinoids. *Eur J Pharmacol* 345:145–153. (1998)

Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation. *Eur J Pharmacol* (1998)

Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J: The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological and therapeutic aspects. *Pharmacol Ther*; 95:137-52. (2002)

Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR: The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. *J Pharmacol Exp Ther* 70:219–227 (1994)

Song ZH, Bonner TI: A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. *Mol Pharmacol* 49:891-6. (1996)

- Stella N**, Schweitzer P, Piomelli D: A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 388:773-778. (1997)
- Stovner LJ**, Zwart JA, Hagen K, Terwindt GM, Pascual J: Epidemiology of headache in Europe. *European Journal of Neurology*, 13: 333–345 (2006)
- Sugiura T**, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun* 215:89-97. (1995)
- Szallasi A** és Blumberg PM: Vanilloid (Capsaicin) receptors and mechanism. *Pharmacol Rev*; 51(2):159-212 (1999)
- Syed YY**, McKeage K, Scott LJ. : Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. *Drugs*. (2014)
- Tassorelli C**, Joseph SA: Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. *Brain Research* 682:167-181, (1995)
- Tassorelli C**, Joseph SA, Nappi G: Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: a pharmacological investigation. *Neuropharmacology* 36:1417–1424, (1997)
- Tassorelli C**, Joseph SA, Buzzi MG, Nappi G: The effects on the central nervous system of nitroglycerin--putative mechanisms and mediators. *Progress in Neurobiology* 57:607-624, (1999)
- Tassorelli C**, Blandini F, Greco R, Nappi G: Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. *Journal of Chemical Neuroanatomy* 27:23-32, (2004)
- Tian X**, Guo J, Yao F, Yang DP, Makriyannis A: The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. *J Biol Chem*. 280:29788-95. (2005)
- Thomsen LL**, Krusse C, Iversen HK, Olesen I: A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. *European Journal of Neurology* 1:73-80, (1994)

Tsou K, Lowitz KA, Hohmann AG, Martin WJ, Hathaway CB, Bereiter DA, Walker JM: Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. *Neuroscience* 70:791–798. (1996)

Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. *Neuroscience*, Pages 393-411 (1997)

Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K: The formalin test: an evolution of the method. *Pain*;51(1):5-17. (1992)

Valerie South: Migrén Hajja & Fiai Könyvkiadó, Debrecen, (2003)

Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J, Hoefnagels WA, Black DF, Sandkuijl LA, Frants RR, Ferrari MD, van den Maagdenberg AM: Novel mutations in the Na⁺, K⁺-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. *Ann Neurol*;54(3):360-6. (2003)

Wallace MJ, Martin BR, DeLorenzo RJ: Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. *Eur J Pharmacol*; 452:295-301 (2002)

Wang H, Nie H, Zhang RX, Qiao JT: Peripheral nitric oxide contributes to both formalin- and NMDA-induced activation of nociceptors: An immunocytochemical study in rats. *Journal of Neuroscience Research* 57:824-829, (1999)

Weiller C, May A, Limmroth V, Jüptner M, Kaube H, Schayck RV, Coenen HH, Diener HC: Brain stem activation in spontaneous human migraine attacks. *Nat Med*; 1(7):658-60 (1995)

Welch SP, Dunlow LD, Patrick GS, Razdan RK: Characterisation of anandamide- and fluoroanandamide-induced antinociception and cross tolerance to delta-9-THC after intrathecal administration to mice: blockade of delta-9-THC-induced antinociception. *J Pharmacol Exp Ther*;273:1235–1244.(1995)

Wolff HG: Headache and Other Head Pain, New York, Oxford University Press (1948)

Woolf CJ: Pain. *Neurobiology of Disease* 7, 504–510 (2000)

Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D és Hogestatt ED: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature*; 400 (6743): 452-457 (1999)